Corrigendum to Comparative effectiveness of Glargine 300 U/mL vs. Degludec 100 U/mL in patients with type 2 diabetes switching from 1° generation basal insulins > Nutr Metab Cardiovasc Dis. 2022 Sep;32(9):2255-2263

Affiliations

¹ Department of Experimental Medicine, Sapienza University of Rome, Italy.
² Department of Medicine, University of Padova, Padua, Italy.
³ CORESEARCH - Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy. Electronic address: nicolucci@coresearch.it.
⁴ Medical Affairs, Sanofi Milan, Italy.
⁵ CORESEARCH - Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy.
⁶ Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.

Published Erratum

Raffaella Buzzetti et al. Nutr Metab Cardiovasc Dis. 2023 Apr.

. 2023 Apr;33(4):920-921.

doi: 10.1016/j.numecd.2023.02.006. Epub 2023 Mar 21.

¹ Department of Experimental Medicine, Sapienza University of Rome, Italy.
² Department of Medicine, University of Padova, Padua, Italy.
³ CORESEARCH - Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy. Electronic address: nicolucci@coresearch.it.
⁴ Medical Affairs, Sanofi Milan, Italy.
⁵ CORESEARCH - Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy.
⁶ Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.

No abstract available

Erratum for

Comparative effectiveness of Glargine 300 U/mL vs. Degludec 100 U/mL in patients with type 2 diabetes switching from 1° generation basal insulins.
Buzzetti R, Fadini GP, Nicolucci A, Larosa M, Rossi MC, Cucinotta D; RESTORE-2 Study Group. Buzzetti R, et al. Nutr Metab Cardiovasc Dis. 2022 Sep;32(9):2255-2263. doi: 10.1016/j.numecd.2022.06.003. Epub 2022 Jun 21. Nutr Metab Cardiovasc Dis. 2022. PMID: 35961826